FDA Hosts Meeting on How Drug Fees Are Really Spent
Published Date: 8/21/2025
Notice
Summary
The FDA is hosting a public meeting to talk about how money from drug user fees is spent and how to make the process clearer and more efficient. This affects drug companies that pay fees for prescription, biosimilar, and generic drugs. They want your ideas soon to help improve transparency and keep things running smoothly without surprises on costs or timing.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
FDA meeting on drug user fees
If you run or work for a company that pays Prescription Drug User Fee Act (PDUFA), Biosimilar User Fee Act (BsUFA), or Generic Drug User Fee Amendments (GDUFA) fees, the FDA is holding a public meeting to discuss how those fee dollars are spent and how to make the process clearer and more efficient. The FDA is asking for public input and ideas to help improve financial transparency and to avoid surprises on costs or timing.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13346 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Medication Guides for Prescription Drug Products
The FDA is updating how it collects info about Medication Guides—those important leaflets that come with some prescription drugs to keep patients safe. This affects drug makers who must follow new rules about what info to include and how to share it. Comments on these changes are open until July 31, 2026, and the update aims to keep patients informed without adding extra costs.
2026-13140 — Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of Oxygenation
The FDA is officially putting the monitor for opioid-induced oxygen problems into a safer, easier-to-manage category called Class II. This change helps make sure the device works well and is safe, while also speeding up patient access to this important tech. The new rules took effect on June 30, 2026, and could lower costs and delays for companies making these monitors.
2026-13139 — Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of Hyperhidrosis
The FDA is officially classifying the skin patch that treats excessive sweating (hyperhidrosis) as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this cool new treatment faster and safer, starting June 30, 2026. Companies making these patches will find it easier and less costly to bring their products to market.
2026-13006 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYALEV
The FDA has officially set the review period for the drug VYALEV, which helps the company extend its patent protection. This means the patent clock can be paused, giving the drug maker more time to sell VYALEV exclusively. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by late 2026.
2026-13005 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; New Animal Drugs for Minor Use and Minor Species
The FDA is asking for public feedback on their plan to keep collecting info about new animal drugs for rare uses and less common species. This affects drug makers who want special approval and incentives for these unique animal medicines. Comments are open until July 29, 2026, and the process helps keep these important drugs safe and available without extra costs.
Previous / Next Documents
Previous: 2025-15935 — Agency Information Collection Activities: Submission for OMB Review; Comment Request
CMS wants your thoughts on their plan to collect info from the public again. This is a chance to share how much time or effort it might take and suggest ways to make it easier. If you’re involved with Medicare or Medicaid, your input can help shape how this info is gathered—no money changes yet, but your voice matters now!
Next: 2025-15937 — ICE Clear Credit LLC; Notice of Filing of an Application for Registration as a Clearing Agency Under Section 17A of the Securities Exchange Act of 1934
ICE Clear Credit LLC wants to officially register as a clearing agency to handle U.S. Treasury securities transactions, like buying and selling government bonds. This change affects banks and traders who deal with these securities, aiming to make the process smoother and safer. The SEC is reviewing the application now, so keep an eye out for updates that could impact how these deals get cleared and settled.